Navigation Links
Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
Date:12/19/2007

FDA Offers Special Protocol Assessment for Reviroc

AMSTERDAM, December 19 /PRNewswire/ -- Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The phase III clinical trial design for Reviroc will focus on patients with Large B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and Orphan Drug Designation application with the FDA within the next few weeks.

"We are very pleased with the outcome of the End of Phase II meeting with the FDA and with the possibility to access the FDA's Special Protocol Assessment program. Together with the strong support by our principal investigators we are well prepared to design a clear path towards marketing authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone-marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone mar
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Clara, California (PRWEB) March 03, 2015 ... development service company, has launched a new Life Science ... reagents for preclinical research. , The first products ... antibody isotype controls, and soon to be released in ... company will continue to expand their life science portfolio ...
(Date:3/3/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... Expert Opinion on Biological Therapy , Dr. ... Zhang , at the Henry Ford Hospital in ... 4 (TB4) has the capacity to promote CNS and ... post-injury, leading to neurological recovery in each case.  They ...
(Date:3/3/2015)... 2015 Becht Engineering Co., Inc., ... has acquired The CECON Group, Inc., located in ... not announced. , Becht Engineering (http://www.becht.com ) ... including oil and gas production, refining, petrochemical, chemical, ... power sectors. The company has twelve offices in ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. , ... viral vectors, nonviral vectors and cell therapy with ... method of drug delivery and various routes of ...
Breaking Biology Technology:Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3
... June 15 Finesse Solutions, LLC, San Jose, CA, a ... its move from a facility in Santa Clara, CA, to ... new address is 71 Daggett Drive, San Jose, CA, 95134. ... from Irvine, CA to Silicon Valley. , , The ...
... MedPredict Market Research, a global provider of pharmaceutical competitive ... entitled "Thought Leader Insight & Analysis: Alzheimer,s Disease," designed ... companies with a stake in the market for diagnostics ... http://www.medpredict.com/website/home.aspx ). , , MedPredict ...
... , - Improving Research ... today announced a new partnership agreement with NextBio,provider of ... discover, and share knowledge locked within public and proprietary,data ... of NextBio,s unique set of ontology-based semantic tools and ...
Cached Biology Technology:New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline 2Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 2Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 3Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 4
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... Mich---University of Michigan researchers have determined that most types ... evidence that the deadliest form of skin cancer does ... model. In addition, the researchers found that melanoma ... genes on and off, making the malignant cells a ...
... WASHINGTON Though the massive glaciers of the greater ... steps now to help the region,s communities prepare for ... their lives, according to a new report. Programs that ... needed to adequately address these impacts, the report states. ...
... Ill. University of Illinois researchers are using a new ... in biology the relationship between cell mass and growth ... and bioengineering professor Rashid Bashir, published its results in the ... Academy of Sciences . "It,s merging micro-scale engineering and ...
Cached Biology News:More evidence that melanoma does not conform to the cancer stem cell model 2More evidence that melanoma does not conform to the cancer stem cell model 3Time to prepare for climate change 2Time to prepare for climate change 3Time to prepare for climate change 4Time to prepare for climate change 5Microsensors offer first look at whether cell mass affects growth rate 2
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
AedestaTM Animal Organ/Tissue Perfusion Soln....
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: